Escolar Documentos
Profissional Documentos
Cultura Documentos
Sitagliptin phosphate Januvia Antidiabetic drug, DPP-4 (dipeptidyl peptidase-4) enzyme inhibitor Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. Administer with or without food and should be taken once a day. Monitor blood glucose levels.
Advise patient to monitor for signs and symptoms of hypoglycemia and to report difficulties with glycemic control.
Advise patient that stress such as fever, trauma, infection, or surgery may require medication dosage adjustments.
Instruct patient to report signs and symptoms of pancreatitis. If persistent severe abdominal pain does occur patient should discontinue and notify the physician immediately.
GENERIC NAME
Furosemide
BRAND NAME
Lasix
DOSAGE
FREQUENCY
ROUTE
CLASSIFICATION
Diuretics
INDICATION
Edema associated with heart failure, cirrhosis, renal disease, acute pulmonary edema, hypertension.
CONTRAINDICATION
Patients with anuria and in patients with a history of hypersensitivity to furosemide.
NURSING RESPONSIBILITY
Assessment History: allergy to furosemide, sulphonamides, tartrazine; severe renal failure; DM; Lactation; pregnancy. Physical: skin color, lesions, edma; orientation, reflexes, hearing; pulses, baseline ECG, BP, orthostatic BP. Administer with food or milk to prevent GI upset. Reduce dosage if given with other antihypertensive s; readjust dosage gradually as BP responds. Give early in the day so that increased urination will not disturb sleep. Avoid use if oral use is at all possible
GENER IC NAME
Amlodipine besylate
BRAN D NAME
Vasalat
DOSA GE
FREQUE NCY
ROUT E
Advise patient to avoid grapefruit or grapefruit juice during therapy. Advise patient to change positions slowly to minimize orthostatic hypotension. Advise patient to wear protective clothing and to use sunscreen to prevent photosensitivity. Monitor blood pressure and pulse prior to administering the drug. Report immediately and swelling, redness, burning, or pain at infusion site. Discontinue the infusion if the patient develops tachycardia or hypotension. Adjust lighting, temperature and noise because headache may occur.